Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers-2025/1/6

Guidance for FDA Staff and Interested Parties: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act-2025/1/6

Guidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children-2025/1/6

Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5)-20251/6

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act-2025/1/6

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act-2025/1/6

Validation and Verification of Analytical Testing Methods Used for Tobacco Products-2025/1/6

Considerations for Complying with 21 CFR 211.110-2025/1/6

Draft Guidance for Industry: E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports-2024/3/13

Draft Guidance: Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products-2024/3/12